MPM BioImpact-backed Orna Therapeutics to acquire ReNAgade Therapeutics.

MPM BioImpact-backed Orna Therapeutics, a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases, agreed to acquire ReNAgade Therapeutics, a biotechnology company that focuses on the potential of RNA therapeutics to treat disease. Financial terms were not disclosed. "RNA-centric approaches are poised to eclipse traditional cell therapy-based methods and reshape the future of medicine. This strategic acquisition unifies Orna's and ReNAgade's strengths and capabilities under one roof, expanding technological synergies and multiplying the companies' depth and breadth of expertise to drive a unique RNA therapeutic-focused R&D engine. Orna will now advance an industry-leading approach combining the Company's circular RNA expression technology with ReNAgade's broad portfolio of LNP-based RNA delivery systems and comprehensive editing programs to solve the most pressing challenges in drug development," Amit D. Munshi, ReNAgade CEO.